Table 2.
Multivariable Cox regression analyses predicting disease recurrence and cancer-specific mortality of 678 patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
| Disease-free survival | Cancer-specific survival | |||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | P value | HR | 95 % CI | P value | |
| Male gender | 0.76 | 0.56–1.04 | 0.085 | 0.78 | 0.56–1.08 | 0.13 |
| Age | 1.02 | 0.99–1.03 | 0.052 | 1.03 | 1.01–1.04 | 0.006 |
| Pathological stage | Ref. | Ref. | ||||
| Ta | ||||||
| T1 | 1.80 | 0.76–4.28 | 0.184 | 1.48 | 0.57–3.80 | 0.42 |
| T2 | 3.58 | 1.52–8.44 | 0.003 | 3.49 | 1.40–8.73 | 0.008 |
| T3 | 7.31 | 3.21–16.65 | <0.001 | 6.29 | 2.58–15.31 | <0.001 |
| T4 | 32.98 | 12.81–84.87 | <0.001 | 25.16 | 9.11–69.53 | <0.001 |
| Pathological high grade | 1.38 | 0.82–2.32 | 0.23 | 1.59 | 0.89–2.82 | 0.12 |
| Lymphovascular invasion | 1.14 | 0.80–1.64 | 0.47 | 1.31 | 0.89–1.92 | 0.16 |
| Concomitant CIS | 1.52 | 1.03–2.23 | 0.035 | 1.06 | 0.69–1.63 | 0.78 |
| Architecture | 1.27 | 0.86–1.86 | 0.23 | 1.35 | 0.89–2.06 | 0.15 |
| Necrosis | 0.46 | 0.29–0.75 | 0.002 | 0.51 | 0.30–0.85 | 0.009 |
| Multifocality | 1.44 | 1.01–2.056 | 0.045 | 1.78 | 1.22–2.58 | 0.003 |
| Kidney location | 1.17 | 0.86–1.60 | 0.32 | 1.26 | 0.90–1.76 | 0.18 |
| Lymph node metastasis | 2.40 | 1.57–3.66 | <0.001 | 2.28 | 1.46–3.55 | <0.001 |
| E-cadherin decreased expression | 1.06 | 0.76–1.48 | 0.74 | 0.96 | 0.68–1.38 | 0.84 |
CI confidence interval, CIS carcinoma in situ, HR hazard ratio